🔗 Share this article

The first new treatments for gonorrhoea in many years are being viewed as a "major milestone" in the effort against increasingly resistant strains of the pathogen, according to health experts.

A Global Public Health Issue

Gonorrhoea infections are increasing around the world, with figures suggesting over 82 million infections each year. Especially elevated rates are observed in the African continent and nations within the WHO's designated area, which spans from Mongolia and China to New Zealand. Across England, cases have reached a record high, while infection numbers across Europe in 2023 were triple the level compared to figures for 2014.

“The clearance of novel therapies for gonorrhoea is an important and timely advancement in the reality of increasing worldwide cases, the spread of superbugs and the highly restricted available drugs currently available.”

Health officials are deeply concerned about the increase in drug-resistant strains. The World Health Organization has listed it as a "priority pathogen". Ongoing monitoring found that the effectiveness of key first-line drugs like ceftriaxone and cefixime increased dramatically between 2022 and 2024.

Two New Treatment Options Gain Approval

Zoliflodacin, also known as a brand name, was authorized by the US FDA in December for use against gonorrhoea. This disease can lead to major issues, including the inability to conceive. Scientists believe that specific application of this new drug will help hinder the spread of drug resistance.

Gepotidacin, developed by the pharmaceutical company GSK, was also approved in the same week. This drug, which is employed against UTIs, was shown in trials to be able to combat superbug versions of the gonorrhoea bacteria.

A Unique Development Model

This new treatment emerged from a unique collaborative effort for antibiotic development. The charitable organization GARDP collaborated with the drug firm its industry partner to bring it to fruition.

“This approval marks a huge turning point in the therapy of highly resistant gonorrhoea, which previously has been outpacing medical innovation.”

Testing Outcomes and Worldwide Availability

Based on results detailed in a major medical journal, the new drug eradicated more than 90% of uncomplicated infections. This places it at an equal footing with the current standard treatment, which combines two antibiotics. The trial enrolled nearly 1,000 patients from various regions including the United States, Thailand, South Africa, and European nations.

Under the terms of its unique model, GARDP has the rights to register and commercialise the drug in many low-income and middle-income countries.

Clinicians treating patients have expressed hope. Having a easy-to-administer therapy of this kind is hailed as a "critical tool" for gonorrhoea control. This is viewed as vital to reduce the burden of the disease for individuals and to prevent the spread of highly drug-resistant gonorrhoea worldwide.